BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu S, Wang H, Hu T, Yu C, Liu H, Chen X, Jiang J, Deng M. Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: An age-period-cohort analysis. Sci Prog 2021;104:368504211018081. [PMID: 34003688 DOI: 10.1177/00368504211018081] [Reference Citation Analysis]
2 Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Djaogol T, Fontaine H, Baudoin M, Protopopescu C, Marcellin F, Dorival C, Simony M, Petrov-Sanchez V, Bourlière M, Delarocque-Astagneau E, Pol S, Carrat F, Carrieri P; ANRS CO22 Hepather study group. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. Liver Int 2021;41:2328-40. [PMID: 33590608 DOI: 10.1111/liv.14823] [Reference Citation Analysis]
4 Santos-Lima C, Souza-Marques B, Vieira F, Isabel Schinoni M, Quarantini LC, Abreu N. Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. J Viral Hepat 2021. [PMID: 34320255 DOI: 10.1111/jvh.13584] [Reference Citation Analysis]
5 Guzman Ramos MI, Manzano-García M, Robustillo-Cortés MLA, Pineda JA, Morillo-Verdugo R. Effect on the adherence to concomitant medications after initiation of treatment with direct-acting antiviral agents against hepatitis C virus. Gastroenterol Hepatol 2020;43:418-25. [PMID: 32279937 DOI: 10.1016/j.gastrohep.2020.02.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 2020;95:84-9. [PMID: 32302766 DOI: 10.1016/j.ijid.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022; 10(6): 1764-1774 [DOI: 10.12998/wjcc.v10.i6.1764] [Reference Citation Analysis]
9 Vaghi G, Gori B, Strigaro G, Burlone M, Minisini R, Barbaglia MN, Brigatti E, Varrasi C, Pirisi M, Cantello R. Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study. J Neurovirol. 2020;26:870-879. [PMID: 32910431 DOI: 10.1007/s13365-020-00904-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rammohan A. Current management & future directions in post-liver transplant recurrence of viral hepatitis. Journal of Liver Transplantation 2021;3:100027. [DOI: 10.1016/j.liver.2021.100027] [Reference Citation Analysis]
12 Ivantes CAP, Silva BCD, Acosta GG, Tawil FBNE, Nisihara R. NON-ADHERENCE TO HEPATITIS C TREATMENT: A BRAZILIAN REPORT. Arq Gastroenterol 2021;58:456-60. [PMID: 34909850 DOI: 10.1590/S0004-2803.202100000-83] [Reference Citation Analysis]
13 Seto MT, Cheung KW, Hung IFN. Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol 2020;68:44-53. [PMID: 32305262 DOI: 10.1016/j.bpobgyn.2020.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 van Riet RC, van Dijk KM, van den Hoogen MWF. New possibilities on transplanting kidneys from hepatitis C virus positive donors: a Systematic Review. Transplant Rev (Orlando) 2020;34:100532. [PMID: 31948862 DOI: 10.1016/j.trre.2020.100532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Tatemichi M, Furuya H, Nagahama S, Takaya N, Shida Y, Fukai K, Owada S, Endo H, Kinoue T, Korenaga M. A nationwide cross-sectional survey on hepatitis B and C screening among workers in Japan. Sci Rep 2020;10:11435. [PMID: 32651421 DOI: 10.1038/s41598-020-68021-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kc S, Murphy H, Dixit S, Rai A, Pradhan B, Lagrange-Xelot M, Karki N, Dureault A, Karmacharya U, Panthi S, Tulachan N, Kc P, Kc A, Rajbhandari R, Trotter AB, Gölz J, Pradat P, Trépo C, Creac'H P. Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal. PLoS Negl Trop Dis 2020;14:e0008931. [PMID: 33326423 DOI: 10.1371/journal.pntd.0008931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zapatero-Belinchón FJ, Ötjengerdes R, Sheldon J, Schulte B, Carriquí-Madroñal B, Brogden G, Arroyo-Fernández LM, Vondran FWR, Maasoumy B, von Hahn T, Gerold G. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells 2021;10:1626. [PMID: 34209751 DOI: 10.3390/cells10071626] [Reference Citation Analysis]
18 Piedade J, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves Ú, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep 2021;11:11681. [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1] [Reference Citation Analysis]